CD274 and small cell lung carcinoma: There had been few improvements in SCLC standard of care management in the decades prior to the IMpower133 results, which demonstrated survival benefit with the addition of the anti–PD-L1 agent atezolizumab to platinum-based chemotherapy for patients with extensive-stage SCLC (8).